Interview with acting CEO Johan Giléus about the Q1 report 2022
Capital Markets Day 2022
InDex Pharmaceuticals would like to raise the awareness of World IBD Day by wearing the Purple Ribbon, an international symbol of inflammatory bowel disease (IBD).
Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
-
Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
June 1, 2022 Regulatory
-
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2022
May 16, 2022 Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q1 for January-March 2022 on May 16, 2021 at 08:00 a.m. CEST.
-
Interim Report Q2 2022
-
Interim Report Q3 2022
-
Year-end Report 2022
Our phase III study CONCLUDE
Have a look at InDex’s corporate presentation
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
